Loading
A phase 3 trial of Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig in biliary tract cancer, run by AstraZeneca, now recruiting.
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer is a phase 3 interventional study registered as NCT06467357 by AstraZeneca, with 620 participants planned, started 2024-08-12 and due to reach its primary completion in 2028-06-12. Interventions recorded: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Shares Durvalumab, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Platinum agents and the tag pipeline.
Shares Rilvegostomig, Durvalumab, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Platinum agents and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/